Affordable Access

deepdyve-link
Publisher Website

Chemogenetics a robust approach to pharmacology and gene therapy.

Authors
  • Keifer, O1
  • Kambara, K2
  • Lau, A1
  • Makinson, S1
  • Bertrand, D3
  • 1 CODA Biotherapeutics, c/o JLabs, 151 Oyster Point Blvd Inc. 2nd Floor, San Francisco, CA 94080, United States. , (United States)
  • 2 HiQScreen Sàrl, 6 rte de Compois, 1222 Vésenaz, Geneva, Switzerland. , (Switzerland)
  • 3 HiQScreen Sàrl, 6 rte de Compois, 1222 Vésenaz, Geneva, Switzerland. Electronic address: [email protected] , (Switzerland)
Type
Published Article
Journal
Biochemical pharmacology
Publisher
New York, NY : Elsevier Science Inc
Publication Date
Feb 28, 2020
Volume
175
Pages
113889–113889
Identifiers
DOI: 10.1016/j.bcp.2020.113889
PMID: 32119836
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Modern developments in organic chemistry, molecular biology, virology, and genetics have opened new, exciting possibilities to better understand physiology and to create innovative, robust therapeutics. One such possibility is the burgeoning field of chemogenetics, a sub-field of chemical genetics that encompasses engineering macromolecules (particularly proteins) to modify how they interact with endogenous and exogenous ligands (particularly small molecules). Early efforts in chemogenetics were focused on parsing the function of a specific enzyme within a closely-related family by creating orthogonal enzyme-ligand pairs (e.g. kinases paired with antagonists). This powerful concept quickly expanded into engineered G-protein-coupled receptors (e.g. DREADDs/RASSL), and more recently into engineered ligand-gated ion channels (eLGIC). The modifications to the receptor focused on eliminating their activation by endogenous ligands, while preserving or enhancing their interaction with pharmacological agents (e.g. small molecule agonist). Creation of such an engineered receptor and delivering it selectively to specific cell types opens new possibilities of accurately and precisely controlling cellular activity. Control of this activity then increases our understanding of the cells function in normal physiology, while also creating the possibility of using it as a therapeutic to address pathophysiology. The DREADDs/RASSL and eLGIC approaches have been particularly impactful in neurosciences but have applications in multiple fields. In this work we introduce the history of the chemogenetic approach, review the seminal work with DREADDs/RASSLs and eLGIC, highlight the breadth of applications, and discuss the strengths and weaknesses associated with this technology, especially in the context of its development into a therapeutic. Copyright © 2020. Published by Elsevier Inc.

Report this publication

Statistics

Seen <100 times